Drugs / CART-PSMA-TGFβRDN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04227275 | Nov 2019 → Nov 2022 | castration-resistant prostate carcinoma | Tceleron Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-PSMA-TGFβRDN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04227275 ↗ |
| Modality | Cell therapy | “genetically modified autologous T cells” NCT04227275 ↗ |
| Route | Intravenous | “safely administered intravenously” NCT04227275 ↗ |